jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Cryptococcus Antigen detection by Agglutination - CSF

Bacterial/ Viral
image

Report in 48Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Measures lactate in CSF.

₹2,590₹3,700

30% OFF

Cryptococcus Antigen Detection by Agglutination - CSF

  • Why is it done?
    • Detects cryptococcal polysaccharide antigens in cerebrospinal fluid (CSF) to diagnose cryptococcal meningitis, a serious fungal infection of the central nervous system
    • Used to confirm cryptococcal infection in patients presenting with meningitis symptoms, particularly those with immunocompromised conditions such as HIV/AIDS, organ transplant recipients, or patients on immunosuppressive therapy
    • Performed when patients present with clinical signs of meningitis including severe headache, fever, neck stiffness, photophobia, altered mental status, and/or neurological symptoms
    • Ordered as part of initial CSF analysis following lumbar puncture when fungal meningitis is suspected based on clinical presentation and preliminary CSF findings
    • Particularly important in diagnostic workup when other common causes of meningitis (bacterial, viral) have been ruled out or when clinical suspicion for cryptococcal infection is high
  • Normal Range
    • Result Interpretation: Negative or Non-Reactive (Normal)
    • A negative result indicates no detectable cryptococcal antigens in the CSF sample, suggesting absence of cryptococcal infection at the time of testing
    • Result Values: May be reported as negative, non-reactive, not detected, or <1:1 titer (in some agglutination methods using dilutional analysis)
    • Units of Measurement: Qualitative (positive/negative) or quantitative (titer, with titers expressed as 1:2, 1:4, 1:8, 1:16, 1:32, etc., depending on dilution where agglutination becomes apparent)
    • Clinical Significance: Normal (negative) results effectively rule out cryptococcal meningitis and allow clinicians to pursue alternative diagnostic considerations for the patient's meningitis or neurological symptoms
  • Interpretation
    • Positive Result (Detected/Reactive):
    • A positive cryptococcal antigen detection confirms cryptococcal meningitis and is highly sensitive and specific for diagnosing this fungal infection of the central nervous system
    • Positive results warrant immediate initiation of antifungal therapy, typically with amphotericin B and flucytosine, followed by fluconazole for consolidation and maintenance therapy
    • Titer Significance: When reported quantitatively, higher titers (e.g., 1:16, 1:32, or greater) may indicate higher antigen loads and more extensive infection; titers correlate with disease severity and can be used to monitor treatment response
    • Factors Affecting Results:
    • Immunocompromised status: Highly sensitive in immunocompromised patients; may show positive results earlier and with higher titers in severe immunosuppression
    • Stage of infection: Positive results typically appear early in infection but may remain positive for weeks to months even after successful treatment initiation
    • Sample quality and handling: Proper CSF collection, storage, and timely processing are essential; contamination or improper handling may affect results
    • False negatives: Rare but possible in very early infection, with severely compromised immune systems affecting antibody response, or with technically inadequate samples
    • Clinical Significance of Different Results:
    • Borderline/weakly positive: May warrant repeat testing or correlation with other diagnostic methods (culture, India ink stain) to confirm diagnosis
    • Strongly positive with high titer: Indicates definitive cryptococcal meningitis requiring urgent treatment and careful monitoring for complications
  • Associated Organs
    • Primary Organ Systems Involved:
    • Central Nervous System (CNS): Primary site of infection in cryptococcal meningitis; involves the meninges, brain, and spinal cord
    • Immune System: Cryptococcal infection indicates significant immunocompromise; commonly associated with advanced HIV/AIDS, post-transplant immunosuppression, or other immunocompromised states
    • Diseases and Conditions Associated with Abnormal Results:
    • Cryptococcal Meningitis: Fungal infection of the meninges caused by Cryptococcus neoformans; most common cause of meningitis in HIV-positive patients with CD4 count <100 cells/μL
    • HIV/AIDS: Advanced immunosuppression (CD4 <100 cells/μL) significantly increases risk of disseminated cryptococcal disease and meningitis
    • Organ Transplant Recipients: Immunosuppressive medications increase susceptibility to opportunistic infections including cryptococcosis
    • Hematologic Malignancies: Patients with lymphoma, leukemia, or other blood cancers on chemotherapy have increased risk of cryptococcal infection
    • Chronic Corticosteroid Use: Long-term high-dose corticosteroids can predispose to opportunistic infections including cryptococcosis
    • Potential Complications of Abnormal Results:
    • Increased Intracranial Pressure (ICP): Cryptococcal meningitis can cause elevated CSF opening pressure and risk of herniation; requires careful management
    • Hydrocephalus: Can develop as a complication of cryptococcal meningitis due to inflammation and obstruction of CSF flow
    • Disseminated Cryptococcosis: May involve lungs, skin, bone, and other organs if not promptly treated
    • Mortality and Morbidity: If untreated, cryptococcal meningitis has high mortality rate; delayed diagnosis and treatment increase risk of neurological sequelae and death
    • Drug Toxicity: Antifungal agents used to treat cryptococcal meningitis (amphotericin B) can cause significant adverse effects requiring close monitoring
  • Follow-up Tests
    • Initial Confirmatory Tests:
    • CSF Culture: Gold standard for confirming cryptococcal meningitis; grows Cryptococcus neoformans; takes 2-7 days or longer for growth
    • India Ink Stain: Microscopic examination of CSF for encapsulated yeast cells; rapid but less sensitive than antigen detection or culture
    • Cryptococcal Antigen (Serum): Blood serum testing for cryptococcal antigen; often positive in disseminated disease and meningitis; helpful for diagnosis and monitoring
    • Associated CSF Parameters:
    • CSF Glucose: Usually low (hypoglycorrhachia) in cryptococcal meningitis; important for differential diagnosis
    • CSF Protein: Typically elevated in cryptococcal meningitis; reflects inflammation of CNS
    • CSF Cell Count and Differential: Lymphocytic pleocytosis is typical; monocytes predominate
    • CSF Opening Pressure: Measurement during lumbar puncture; often elevated in cryptococcal meningitis
    • Imaging Studies:
    • Brain MRI with contrast: Visualizes meningeal enhancement, detects cryptococcomas (mass lesions), hydrocephalus, and complications
    • CT Scan of Brain: May detect elevated ICP signs, hydrocephalus, or other complications; less detailed than MRI but more readily available in emergencies
    • Chest X-ray: To evaluate for pulmonary cryptococcosis, which may coexist with meningitis
    • Immunological Assessment:
    • CD4 Count (if HIV status unknown): Determines degree of immunosuppression; CD4 <100 cells/μL indicates very high risk
    • HIV Testing: Essential if HIV status unknown; cryptococcal meningitis is an AIDS-defining illness
    • Monitoring During Treatment:
    • Repeat CSF Antigen Testing: May be performed at 2 weeks and 10 weeks to assess treatment response; declining titers indicate improvement
    • Repeat Lumbar Puncture: May be indicated after 2 weeks of therapy to assess CSF parameters, opening pressure, and clinical response; also for pressure relief if elevated ICP
    • Serum Antigen Testing: Repeat serum cryptococcal antigen during and after treatment to monitor response
    • Monitoring Frequency:
    • During induction therapy (first 2 weeks): Weekly clinical assessment and CSF parameters if clinically indicated
    • During consolidation/maintenance therapy: Regular monitoring with repeat antigen testing at 2 weeks and 10 weeks
    • After treatment completion: Periodic follow-up testing and clinical assessment to detect recurrence or relapse
  • Fasting Required?
    • Fasting Status: No - Fasting is NOT required for this test
    • Duration: Not applicable; patient may eat and drink normally before the procedure
    • Procedure Requirements:
    • Lumbar Puncture (Spinal Tap): This test requires cerebrospinal fluid collection via lumbar puncture procedure, typically performed in hospital or outpatient setting
    • Patient positioning: Performed with patient in flexed spine position (fetal position) to maximize intervertebral spacing for needle insertion
    • Skin sterilization: Local anesthesia (lidocaine) applied before lumbar puncture; skin cleansed with antiseptic solution to reduce infection risk
    • Medications to Avoid:
    • Anticoagulants: May need to be temporarily discontinued (warfarin, novel anticoagulants) to reduce bleeding risk during lumbar puncture; consult with physician
    • Antiplatelet agents: Aspirin and NSAIDs may increase bleeding risk; may need temporary discontinuation per physician guidance
    • Other Patient Preparation:
    • Informed consent: Patient should understand procedure risks and benefits; sign consent form before lumbar puncture
    • Baseline imaging: Brain CT or MRI may be indicated before lumbar puncture to exclude contraindications (mass effect, herniation risk)
    • Coagulation assessment: Platelet count and coagulation studies (PT/INR, aPTT) should be checked before procedure
    • Empty bladder: Patient should void before procedure for comfort and to reduce complications
    • Post-procedure: Bed rest for 30 minutes to 2 hours recommended; hydration and rest to minimize post-lumbar puncture headache; monitor for complications such as infection, bleeding, or neurological deterioration

How our test process works!

customers
customers